Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antidepressant therapy: new targets for drug development
Autore:
Shelton, RC;
Titolo Testata:
EXPERT OPINION ON THERAPEUTIC PATENTS
fascicolo: 11, volume: 11, anno: 2001,
pagine: 1693 - 1711
SICI:
1354-3776(200111)11:11<1693:ATNTFD>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORTICOTROPIN-RELEASING-FACTOR; MILD STRESS MODEL; NEUROKININ RECEPTOR ANTAGONISTS; PITUITARY-ADRENAL AXIS; MESSENGER-RNA EXPRESSION; NEUROPEPTIDE-Y; NMDA RECEPTOR; DEPRESSED-PATIENTS; CEREBROSPINAL-FLUID; MAJOR DEPRESSION;
Keywords:
antidepressant; corticotropin releasing hormone (CRH); depression; mood disorder; neurokinins; neuropeptide Y; NMDA; substance P;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
184
Recensione:
Indirizzi per estratti:
Indirizzo: Shelton, RC 1500 21st Ave,S Suite 2200, Nashville, TN 37212 USA 1500 21stAve,S Suite 2200 Nashville TN USA 37212 N 37212 USA
Citazione:
R.C. Shelton, "Antidepressant therapy: new targets for drug development", EXPERT OP T, 11(11), 2001, pp. 1693-1711

Abstract

Antidepressant drugs have been available for more than 40 years. However, essentially all drugs currently available share the common mechanism of modulating the synaptic transmission of the monoamines serotonin (5-HT), noradrenaline (NE), or dopamine (DA). The mechanisms of action of available drugs include the enhancing the synaptic availability of the monoamines via blockade of the high-affinity transporter proteins for these transmitters or alpha -1 receptors, or antagonism of 5-HT receptors. Although the available medications are often effective, treatment resistance is common and many patients discontinue prematurely because of side effect problems. More recently, evidence has accumulated suggesting that antidepressants may have effects beyond the postsynaptic receptors. Enhancement or inhibition of mRNA expression for a number of polypeptides have been demonstrated. These proposedultimate effects of antidepressant agents, such as increasing the expression of glucocorticoid receptors and brain derived neurotrophic factor or inhibition of NMDA receptor subunit and corticotropin releasing hormone (CRH) expression, relate to possible new therapeutic targets for antidepressant development. This paper will present data supporting potential new drug targets: antagonists for CRH, NMDA, neurokinins and agonists for neuropeptide Y-1 receptors, as well as reviewing recent relevant patents. The problems with establishing new antidepressant agents will also be discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 06:11:47